EYE National Vision Holdings, Inc.
Ophthalmic Goods · Nasdaq · SEC CIK 1710155 · Fiscal year ends 01/02
Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY2,964.0%
TTM EPS YoY2,833.3%
Revenue 3-yr CAGR4.5%
Net income 3-yr CAGR—
Margins
Gross margin58.8%
Operating margin5.1%
Net margin3.2%
FCF margin3.3%
EBITDA margin9.6%
Returns
ROE7.5%
ROA3.3%
ROIC (approx.)7.2%
Asset turnover1.04x
Leverage & solvency
Liabilities / assets55.0%
Debt / equity0.25x
Current ratio0.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.24x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-01-03 | FY20242024-12-28 |
|---|---|---|
| Income statement | ||
| Revenue | $1.99B | $1.82B |
| Cost of revenue | $819.47M | $764.06M |
| Gross profit | $1.17B | $1.06B |
| SG&A expense | $1.02B | $938.52M |
| Operating income | $58.83M | -$10.36M |
| Pretax income | $41.68M | -$25.68M |
| Income tax | $12.08M | $1.48M |
| Net income | $29.60M | -$28.50M |
| EBITDA | $149.98M | $80.99M |
| EPS (basic) | 0.37 | -0.36 |
| EPS (diluted) | 0.37 | -0.36 |
| Weighted avg. shares (diluted) | 80.58M | 78.59M |
| Balance sheet | ||
| Cash & equivalents | $38.71M | $75.24M |
| Receivables | $57.32M | $49.94M |
| Inventory | $89.32M | $93.92M |
| Current assets | $225.72M | $249.83M |
| PP&E, net | $344.62M | $362.18M |
| Goodwill | $700.64M | $698.30M |
| Intangibles | $7.55M | $8.27M |
| Total assets | $1.98B | $2.01B |
| Current liabilities | $412.41M | $468.27M |
| Short-term debt | $13.25M | $98.02M |
| Long-term debt | $223.24M | $239.15M |
| Total debt | $236.49M | $337.17M |
| Total liabilities | $1.11B | $1.19B |
| Shareholders' equity | $869.53M | $816.33M |
| Net debt | $197.78M | $261.93M |
| Shares outstanding | 79.42M | 78.78M |
| Cash flow statement | ||
| Operating cash flow | $146.29M | $133.65M |
| Capital expenditure | $72.84M | $95.50M |
| Free cash flow | $73.45M | $38.14M |
| Investing cash flow | -$76.61M | -$96.09M |
| Financing cash flow | -$104.62M | -$113.34M |
| Depreciation & amortization | $91.15M | $91.35M |
| Stock-based compensation | $23.69M | $16.71M |
| Share buybacks | $3.21M | $3.09M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.